Early Tafolecimab Treatment After Heart Artery Procedure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting the cholesterol-lowering drug tafolecimab (a PCSK9 inhibitor) early after a heart procedure (PCI) can help people with acute coronary syndrome. It may help lower LDL cholesterol and reduce future heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a non-ST-elevation heart attack or unstable angina (NSTE-ACS).
- You have had a procedure (PCI) to open blocked arteries in your heart.
- Your LDL cholesterol level is between 1.8 and 3.4 mmol/L (about 70–130 mg/dL).
- You do not have severe heart failure, uncontrolled arrhythmias, or poorly controlled blood pressure.
- You do not have serious liver or kidney problems, and you are not allergic to statins or injections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a PCSK9 inhibitor (a strong cholesterol-lowering medicine) before a procedure to open blocked heart arteries can help patients who are having a heart attack. It may reduce damage and improve recovery.
This trial tests a new cholesterol-lowering drug (Tafolecimab) in people who recently had a stroke or mini-stroke caused by plaque buildup in the arteries. The goal is to see if aggressive treatment can reduce the risk of another event.
This trial tests a new injectable drug called tafolecimab to see if different dosing intervals work well for people with high cholesterol who are already on a stable statin dose. If your cholesterol (LDL-C) is still not at your goal, adding tafolecimab might help.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.